Trial Profile
Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms DREAM; GERCOR DREAM
- 20 Jan 2018 Results of a post-hoc analysis evaluating clinical outcomes according to KRAS mutational status and Primary tumor sidedness presented at the 2018 Gastrointestinal Cancers Symposium
- 07 Jun 2016 Results of health-related quality of life data presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 13 Oct 2015 Results (n=452) published in the Lancet Oncology